Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) have earned a consensus rating of “Moderate Buy” from the nine research firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $17.50.

A number of brokerages recently issued reports on FOLD. Guggenheim increased their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday. Morgan Stanley reduced their price target on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Cantor Fitzgerald boosted their price target on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Thursday. JPMorgan Chase & Co. reduced their price target on shares of Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating on the stock in a research report on Friday, August 16th. Finally, StockNews.com lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday.

Amicus Therapeutics Price Performance

Shares of Amicus Therapeutics stock opened at $10.98 on Friday. The company has a debt-to-equity ratio of 2.93, a current ratio of 2.75 and a quick ratio of 2.26. Amicus Therapeutics has a fifty-two week low of $9.02 and a fifty-two week high of $14.57. The firm has a fifty day moving average price of $11.14 and a two-hundred day moving average price of $10.61. The company has a market cap of $3.26 billion, a PE ratio of -28.15 and a beta of 0.68.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.05). Amicus Therapeutics had a negative net margin of 26.23% and a negative return on equity of 41.47%. The company had revenue of $126.67 million during the quarter, compared to analysts’ expectations of $121.21 million. During the same quarter in the prior year, the company posted ($0.15) EPS. The business’s revenue was up 34.0% on a year-over-year basis. Analysts expect that Amicus Therapeutics will post -0.06 EPS for the current year.

Insider Buying and Selling

In related news, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $10.60, for a total transaction of $79,500.00. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $9,398,532.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $10.60, for a total value of $79,500.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $9,398,532.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Bradley L. Campbell sold 7,901 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $12.50, for a total transaction of $98,762.50. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $11,083,175. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 30,401 shares of company stock valued at $352,038 over the last ninety days. Insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On Amicus Therapeutics

Large investors have recently bought and sold shares of the company. OLD Second National Bank of Aurora bought a new stake in Amicus Therapeutics in the third quarter valued at approximately $26,000. Hazlett Burt & Watson Inc. increased its stake in Amicus Therapeutics by 156.9% in the third quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 1,569 shares in the last quarter. Blue Trust Inc. increased its stake in Amicus Therapeutics by 1,705.4% in the third quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 2,831 shares in the last quarter. Arcadia Investment Management Corp MI acquired a new position in shares of Amicus Therapeutics in the third quarter valued at approximately $32,000. Finally, Headlands Technologies LLC acquired a new position in shares of Amicus Therapeutics in the second quarter valued at approximately $89,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.